SeraGene Therapeutics develops RNA-based therapies that utilize liver-targeting drug delivery systems to restore hemostasis by modulating clotting protein expression in patients with coagulation disorders. The company focuses on providing long-lasting treatment options for rare bleeding disorders, thrombotic conditions, and enhancing transfusable platelets, thereby improving the quality of life for affected individuals.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for coagulation disorders often fall short of providing long-lasting control over disordered coagulation, leading to a diminished quality of life for affected individuals. Existing care standards have limitations, particularly for rare bleeding disorders, thrombotic conditions, and platelet dysfunction. Women and girls with bleeding disorders are disproportionately burdened by uncontrolled bleeding.
Solution
SeraGene Therapeutics is developing innovative RNA-based therapies designed to provide long-lasting control over disordered coagulation. Their approach utilizes proprietary RNA agents with liver-targeting drug delivery vehicles to precisely modulate the endogenous expression of clotting proteins in the blood, restoring hemostasis. The company's diverse portfolio of targets and technologies offers a suite of novel approaches for addressing the complex drivers of coagulation, with a focus on high efficacy targets and lower potential safety risks. SeraGene is developing prophylactic therapies for rare bleeding disorders, enhancing transfusable platelets, and creating prophylactic therapies for thrombotic disorders.
Target Audience
The primary target audience includes individuals with coagulation disorders, specifically those with rare bleeding disorders, thrombotic conditions, and inherited or acquired platelet dysfunction, as well as women and girls disproportionately burdened by uncontrolled bleeding.
Features
- Liver-targeting drug delivery system for precise modulation of clotting protein expression.
- RNA-based therapeutics designed for long-lasting control over disordered coagulation.
- Portfolio includes assets in development ranging from discovery to late preclinical phase.
- Focus on developing prophylactic therapies for rare bleeding disorders to enhance patients’ quality of life.
- Technology to enhance the stability and therapeutic functionality of transfusable platelets for individuals with inherited or acquired platelet dysfunction.
- Development of short and long-term prophylactic therapies for thrombotic disorders to manage thrombosis effectively while minimizing side effects.
- Preclinical data in large-animal disease models showing promising outcomes for lead assets.